Valuation
- Market cap
- 3,998,000
- Revenue TTM
- $2,050,000
- Net income TTM
- $-3,740,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -182.44%
- Debt to equity
- 0.00
Trading
- Volume
- 188,300
- Avg volume
- 88,504
- Day's range
- $0.26 – $0.28
- Shares out
- 12,770,000
- Stochastic %K
- 1%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- $2.00
Company profile
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups....
Show more
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
- Industry
- Medical Devices
- Sector
- Healthcare
- Phone
- 240 453 6339
- Website
- https://2020biolabs.com
- Address
- 15810 Gaither Road, Suite 235, Gaithersburg, United States
Latest news
No headlines yet.
